Debbie Cohen, MD
Renal Electrolyte and Hypertension
Accepting new patients
Sees patients age 18 and up
Penn Renal Electrolyte and Hypertension Perelman
View 1 additional location
Headshot of Debbie Cohen, MD
Penn Medicine Provider

About me

  • Director, Hypertension
  • Director, Pheochromocytoma/Paraganglioma Neuroendocrine Tumor Program
  • Professor of Medicine (Renal-Electrolyte and Hypertension) at the Hospital of the University of Pennsylvania

Education and training

  • Medical School: University of the Witwatersrand University Medical School
  • Residency: Hillbrow Hospital
  • Residency: Johannesburg General Hospital (Charlotte Maxeke)
  • Residency: Albert Einstein Medical Center
  • Fellowship: University of Pennsylvania Health System

What my patients think about me

Average Rating

522 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Anonymous
February 2026
Dr. Cohen listened to me and clearly explained her instructions.
Anonymous
February 2026
Dr. Cohen is the best and i am very grateful to have her as my doctor.
Anonymous
February 2026
long time patient
Anonymous
February 2026
ive been a patient of dr cohens for over 20 years

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Cohen is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Sunderraj A, Cai X, Pasch A, Feinstein M, Mehta R, Srivastava A, Ricardo AC, Cohen DL, Isakova T. Associations of calciprotein particle maturation time with echocardiographic measures in the CRIC Study. , Am J Nephrol. : 2026


Dardari ZA, Yao Z, Zhang J, Bakoyannis G, Nan H, Staten LK, Jha KK, Tasdighi E, Jelwan Y, Burka S, Matsushita K, Simonsick EM, Lima JAC, Psaty BM, Cohen DL, Appel LJ, Khera A, Shah AM, Hall ME, Judd SE, Cole SA, Vasan RS, Benjamin EJ, Cawthon PM, Orwoll E, LaMonte MJ, Eaton CB, El Khoudary SR, Thurston RC, Derby CA, Lotufo PA, Bensenor IM, Bittencourt MS, Blaha MJ. Prospective Associations of Obesity and Obesity Severity With 9 Cardiovascular Outcomes: The Cross-Cohort Collaboration. , Circulation. , 153(10): 2026,720-735


Estrada-Zuniga C, Liang R, Landry B, Alvarez A, Gonzalez-Cantu H, Nascimento da Conceição V, Trevino R, Gius D, Asa SL, Powers J, Prodanov T, Vaidya A, Toledo RA, Bayley JP, Cohen DL, Tischler AS, Pacak K, Li F, Dahia PLM. Identifying TMEM127-deficient pheochromocytomas/paragangliomas via RET overexpression by immunohistochemistry. , Res Sq : 2026


Blinder AR, Sapiro D, Baker JE, Qin Z, Bancos I, Lyden ML, Young WF, Wachtel H, Cohen DL, Kürzinger L, Fassnacht M, Luther JM, Williams TA, Reincke M, Turcu AF, Else T, Giordano TJ, Udager AM, Rainey WE, Nanba K. Adrenal histologic and genetic characteristics of primary aldosteronism in late adulthood. , Eur J Endocrinol., 194(2): 2026,208-216


Pregnall AM, Wubbenhorst B, D'Andrea K, Pluta J, Amjad W, Shilan J, Cohen DL, Weathers B, Bennett B, Bonanni M, Montone K, Nathanson KL, Wachtel H. Metastatic progression of pheochromocytoma and paraganglioma occurs via parallel evolution. , NPJ Precis Oncol. : 2026


White WB, Azizi M, Ferdinand K, Cohen DL, Nührenberg T, Lefkowitz M, Jiao R, Rizkala AR, Maboudian M, Williams B. Natriuretic Peptide Receptor-1 Agonist for Resistant Hypertension: A Randomized Phase 2 Trial. , J Am Coll Cardiol. 2026 Jan 13:S0735-1097(25)10351-3. doi: 10.1016/j.jacc.2025.11.045. Epub ahead of print. PMID: 41563174., S0735-1097(25): 2026,10351-10353


Estrella MM, Ballew SH, Sang Y, Grams ME, Coresh J, Surapaneni A, Alencar de Pinho N, Ärnlöv J, Brenner H, Carrero JJ, Chen TK, Cohen DL, Cushman M, Gansevoort RT, Hwang SJ, Inker LA, Ix JH, Kabasawa K, Konta T, Lees JS, Polkinghorne KR, Shlipak MG, Vernooij RWM, Wheeler DC, Yadav AK, Levey AS, Eckardt KU; Chronic Kidney Disease Prognosis Consortium Investigators and Collaborators. Discordance in Creatinine- and Cystatin C-Based eGFR and Clinical Outcomes: A Meta-Analysis. , JAMA. , 334(21): 2025,1915-1926


Tasdighi E, Yao Z, Dardari ZA, Jha KK, Osuji N, Rajan T, Boakye E, Matsushita K, Simonsick EM, Lima JAC, Lloyd-Jones DM, Cohen DL, Appel LJ, Khera A, Hall ME, Rodriguez CJ, Judd S, Cole SA, Ramachandran VS, Benjamin EJ, Lotufo PA, Bittencourt MS, El Khoudary SR, Thurston RC, Derby CA, Psaty BM, Eaton CB, LaMonte MJ, Cawthon PM, Orwoll ES, Bhatnagar A, DeFilippis AP, Blaha MJ. Association between cigarette smoking status, intensity, and cessation duration with long-term incidence of nine cardiovascular and mortality outcomes: The Cross-Cohort Collaboration (CCC). , PLoS Med. , 22(11): 2025,e1004561


Shulman R, Yang W, Cohen DL, Reese PP, Cohen JB; CRIC Study Investigators. Renin-Angiotensin System Inhibitors in Patients With Nonproteinuric Chronic Kidney Disease and Kidney Outcomes: Findings From the CRIC Study. , Kidney Med. , 8(1): 2025,101159


van Rooyen D, Bandulik S, Coon GA, Laukemper M, Kumar-Sinha C, Udager AM, Lerario AM, Lee C, Wachtel H, Cohen DL, Luther JM, Giordano TJ, Scholl UI, Butz F, Popp B, Turcu AF, Warth R, Rainey WE, Rege J. Somatic Mutations in MCOLN3 Are Associated With Aldosterone-Producing Adenomas. , Hypertension. : 2025